An emergency use authorization for a COIVD-19 vaccine might be appropriate following strong Phase II data if product use is limited to a very narrow and high-risk population, three former US FDA leaders in vaccine and countermeasures work told the Pink Sheet.
But FDA should exercise extreme caution in issuing an emergency use authorization for a COVID-19 vaccine, these past leaders and...







